Prevention of hip fractures in long-term care: Relevance of community-derived data

Journal of the American Geriatrics Society

Volumn 58, Issue 4, 2010, Pages 738-745

  Crilly, Richard G ^a,b,c   Hillier, Loretta M ^a,b   Mason, Michelle ^d   Gutmanis, Iris ^a,b   Cox, Lizebeth ^d  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c Faculty of Medicine   (France)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Falls; Hip fractures; Long term care; Osteoporosis; Prevention

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; PARATHYROID HORMONE[1-34]; VITAMIN D; ZOLEDRONIC ACID;

AGE DISTRIBUTION; CLINICAL TRIAL; DRUG EFFICACY; FALLING; FRAIL ELDERLY; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; NURSING HOME PATIENT; OSTEOPOROSIS; PRIMARY PREVENTION; REVIEW;

ACCIDENTAL FALLS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CANADA; CLINICAL TRIALS AS TOPIC; DATA COLLECTION; EVIDENCE-BASED PRACTICE; FEMALE; FRAIL ELDERLY; HIP FRACTURES; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; NURSING HOMES; OSTEOPOROSIS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN;

EID: 77950433198     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.02766.x     Document Type: Review

References (80)

1. Brown JP, Josse RG for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002 167 (Suppl 10):S1 S36.
2. Brown JP, Fortier M. Canadian consensus conference on osteoporosis, 2006 update. J Obs Gyn Can 2006 28:S95 S112.
3. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992 327:1637 1642.
4. Chapuy MC, Arlot ME, Delmas PD et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994 308:1081 1082.
5. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 344:1434 1441. (Pubitemid 32402100)
6. Chevalley T, Rizzoli R, Nydegger V et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin D-replete elderly patients. Osteoporos Int 1994 4:245 252. (Pubitemid 24291432)
7. Reid IR, Ames RW, Evans MC et al. Long-term effects of calcium Supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial. Am J Med 1995 98:331 335.
8. Ellerington MC, Hillard TC, Whitcroft SI et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996 59:6 11. (Pubitemid 26235001)
9. Overgaard K, Hansen MA, Jensen SB et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ 1992 305:556 561.
10. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 2000 11:83 91.
11. Roux C, Seeman E, Eastell R et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004 20:433 439. (Pubitemid 38525150)
12. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000 85:3109 3115.
13. Tucci JR, Tonino RP, Emkey RD et al. Effect of three years of oral treatment in postmenopausal women with osteoporosis. Am J Med 1996 101:488 501. (Pubitemid 126335969)
14. Brown JP, Kendler DL, McClung MR et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002 71:103 111. (Pubitemid 36935474)
15. Downs RW, Bell NH, Ettinger MP et al. Comparison of Alendronate and internasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000 85:1783 1788. (Pubitemid 32269276)
16. Greenspan SL, Parker RA, Ferguson L et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Min Res 1998 13:1431 1438. (Pubitemid 28418909)
17. Herd RJ, Balena R, Blake GM et al. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, double-blind, placebo-controlled study. Am J Med 1997 103:92 99. (Pubitemid 27352112)
18. Meunier PJ, Confavreux E, Tupinon I et al. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 1997 82:2784 2791. (Pubitemid 27385624)
19. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002 288:321 333.
20. Grant AM, Avenell A, Campbell MK et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium or vitamin D, RECORD): A randomised placebo-controlled trial. Lancet 2005 365:1621 1628.
21. Porthouse J, Cockayne S, King C et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005 330:1003 1006. (Pubitemid 40604285)
22. Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996 18:629 632. (Pubitemid 26257886)
23. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001 344:333 340. (Pubitemid 32107641)
24. Hosking D, Chilvers CED, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998 338:485 492. (Pubitemid 28103131)
25. Ravn P, Bidstrup M, Wasnich RD et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study: A randomized, controlled trial. Ann Intern Med 1999 131:935 942. (Pubitemid 30005033)
26. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000 343:604 610. (Pubitemid 30659471)
27. Kurland ES, Cosman F, McMahon DJ et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects of bone mineral density and bone markers. J Clin Endocrinol Metab 2000 85:3069 3070.
28. Orwoll E, Scheele WH, Calancy AD et al. Recombinant human parathyroid hormone (1-34) therapy reduces the incidence of moderate/severe vertebral fractures in men with low bone density. J Bone Miner Res 2001 16 (Suppl):S162.
29. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 -cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomized double blind controlled trial. BMJ 2003 326:469 472. (Pubitemid 36269626)
30. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fractures. N Eng J Med 2007 357:1799 1809. (Pubitemid 350044800)
31. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 348:1535 1541.
32. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial (FIT) Research Group. J Clin Endocrinol Metab 2000 85:4118 4124.
33. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998 280:2077 2082.
34. Quandt SA, Thompson DE, Schneider DL et al. Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: The Fracture Intervention Trial. Mayo Clin Proc 2005 80:343 349.
35. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999 282:1344 1352.
36. Mellstrom DD, Sorensen OH, Goemaere S et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004 75:462 468. (Pubitemid 40174503)
37. Sorensen OH, Crawford GM, Mulder H et al. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone 2003 32:120 126. (Pubitemid 36299139)
38. Harrington JT, Ste-Marie LG, Brandi ML et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004 74:129 135. (Pubitemid 38263854)
39. Fogelman I, Ribot C, Smith R et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000 85:1895 1900. (Pubitemid 32269295)
40. Heaney RP, Zizic TM, Fogelman I et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002 13:501 505. (Pubitemid 34742210)
41. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995 333:1437 1443.
42. Clemmesen B, Ravn P, Zegels B et al. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 1997 7:488 495. (Pubitemid 27443076)
43. Devogelaer JP, Broll H, Correa-Rotter R et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over three years in postmenopausal women with osteoporosis. Bone 1996 18:141 150. (Pubitemid 26092594)
44. Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999 9:461 468. (Pubitemid 29231740)
45. Storm T, Thamsborg G, Steiniche T et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990 322:1265 1271. (Pubitemid 20152489)
46. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990 323:73 79. (Pubitemid 20221642)
47. Black DM, Delmas PD, Eastell MD et al. Once-yearly zoledronic acide for treatment of postmenopausal osteoporosis. N Engl J Med 2007 356:1809 1822. (Pubitemid 46698462)
48. Recker RR, Hinders S, Davies KM et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Min Res 1996 11:1961 1966. (Pubitemid 26425690)
49. Chesnut CH III., Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. The Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000 109:267 276.
50. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985 102:319 324. (Pubitemid 15134678)
51. Lufkin EG, Wahner HW, O'Fallon WM et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992 117:1 9.
52. Nachtigall LE, Nachtigall RH, Nachtigall RD et al. Estrogen replacement therapy I: A 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979 53:277 281. (Pubitemid 9110947)
53. Chapuy MC, Pamphile R, Paris E et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporos Int 2002 13 (Suppl 1):S25.
54. Colon-Emeric CS, Lyles KW, House P et al. Randomized trial to improve fracture prevention in nursing home residents. Am J Med 2007 120:886 892. (Pubitemid 47451293)
55. Lyons RA, Johansen A, Brophy S et al. Preventing fractures among older people living in institutional care: A pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporos Int 2007 18:811 818. (Pubitemid 46684786)
56. Meyer HE, Smedshaug GB, Kvaavik E et al. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Min Res 2002 17:709 715. (Pubitemid 34246647)
57. Garg AX, Papaioannou A, Ferko N et al. Estimating the prevalence of renal insufficiency in seniors requiring long term care. Kidney Int 2004 65:649 653. (Pubitemid 38130661)
58. Tanner AD. Analysis of Hip Fracture Patterns in London, Ontario 2002-2006. Master of Science Thesis. London (ON), University of Western Ontario, 2008.
59. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003 21:1383 1389.
60. Dzewaltowski DA, Estabrooks L, Klesges LM et al. Behavior change interventions in community settings: How generalizable are the results? Health Promot Int 2004 19:235 245.
61. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PloS Clin Trials 2006 1:e9.
62. Siris ES, Chen YT, Abbott TA et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004 164:1108 1112.
63. Wainwright SA, Marshall LM, Ensrud KE et al. Hip fracture in women with osteoporosis. J Clin Endocrinol Metab 2005 90:2787 2793.
64. Talbot LA, Musiol RJ, Witham EK et al. Falls in young, middle-aged and older community dwelling adults: Perceived cause, environmental factors and injury. BMC Pub Health 2005 5:86.
65. Nevitt MC, Cummings SR. Type of fall and risk of hip and wrist factures: The study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 1993 41:1226 1234.
66. Hayes WC, Myers ER, Robinovitch SN et al. Etiology and prevention of age-related hip fractures. Bone 1996 18 (Suppl 1):77S 86S.
67. Troy LT, Grabiner MD. Asymmetrical ground impact of the hands after a trip induced fall: Experimental kinematics and kinetics. Clin Biomech 2007 22:1088 1095.
68. van den Kroonenberg AJ, Hayes WC, McMahon TA. Hip impact velocities and body configurations for voluntary falls from standing height. J Biomechanics 1995 29:804 811.
69. Latz JC, Hayes WC. The use of quantitative computed tomography to estimate risk of fracture of the hip from falls. J Bone Joint Surg Am 1990 72:707 707.
70. Rubenstein LZ, Josephson KR, Robbins A. Falls in the nursing home. Ann Intern Med 1994 121:442 451.
71. Melton LJ III., Beard MC, Kokmen E et al. Fracture risk in patients with Alzheimer's disease. J Am Geriatr Soc 1994 42:614 619.
72. Johansson C, Skoog I. A population-based study on the association between dementia and hip fractures in 85-year olds. Aging (Milano) 1996 8:189 196.
73. Buchner DM, Larson EB. Falls and fractures in patients with Alzheimer-type dementia. JAMA 1987 257:1492 1495.
74. Springer S, Giladi N, Peretz C et al. Dual-tasking effects on gait variability: The role of aging, falls, and executive function. Mov Disord 2006 21:950 957.
75. Beauchet O, Annweiler C, Allali G et al. Recurrent falls and dual task-related decrease in walking speed: Is there a relationship? J Am Geriatr Soc 2008 56:1265 1269.
76. Morin S, Rahme E, Behlouli H et al. Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteo Int 2007 18:1625 1632.
77. Ettinger MP. Aging bone and osteoporosis, strategies for preventing fractures in the elderly. Arch Intern Med 2003 163:2237 2246.
78. Lems WF. Bisphosphonates and glucocorticoids: Effects on bone quality. Arthr Rheumatol 2007 56:3518 3522.
79. Chandler JM, Zimmerman SI, Girman CJ et al. Low bone mineral density and risk for fracture in white female nursing home residents. JAMA 2000 284:975 977.
80. Aspray TJ, Stevenson P, Abdy SE et al. Low bone mineral density measurement in care home residents - a treatable cause of fracture. Age Ageing 2006 35:37 41.